Suppr超能文献

头孢哌酮-舒巴坦组合的体外抗菌谱、协同作用的发生情况以及稀释药敏试验浓度的建议。

In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combination.

作者信息

Jones R N, Barry A L, Packer R R, Gregory W W, Thornsberry C

机构信息

Clinical Microbiology Institute, Tualatin, Oregon 97062.

出版信息

J Clin Microbiol. 1987 Sep;25(9):1725-9. doi: 10.1128/jcm.25.9.1725-1729.1987.

Abstract

Broth microdilution tests and an antimicrobial interaction (synergy) studies using various combinations of cefoperazone and sulbactam were performed in an effort to determine the most appropriate in vitro dilution test system. The test results with cefoperazone and sulbactam were categorized as synergistic (complete or partial) for nearly 80% of the strains isolated from clinical trial patients. The results indicate that the cefoperazone-sulbactam fixed ratio (2:1) maximized the cefoperazone spectrum of activity and best approximated the parenteral formulation of the drug. The cefoperazone-sulbactam combination had a greater antimicrobial activity than did the other comparison beta-lactams, except for imipenem, tested against strains of the family Enterobacteriaceae. To be consistent with the National Committee for Clinical Laboratory Standards interpretive breakpoints for cefoperazone alone, the following MIC breakpoints should be applied to the combination (2:1 ratio): less than or equal to 16/8 micrograms/ml, susceptible; 32/16 micrograms/ml, moderately susceptible; and greater than or equal to 64/32 micrograms/ml, resistant.

摘要

进行了肉汤微量稀释试验以及使用头孢哌酮和舒巴坦的各种组合进行的抗菌相互作用(协同作用)研究,以确定最合适的体外稀释试验系统。从临床试验患者中分离出的近80%的菌株,头孢哌酮和舒巴坦的试验结果被归类为协同(完全或部分)。结果表明,头孢哌酮-舒巴坦固定比例(2:1)使头孢哌酮的活性谱最大化,并且最接近该药物的肠胃外制剂。除亚胺培南外,头孢哌酮-舒巴坦组合对肠杆菌科菌株的抗菌活性高于其他比较性β-内酰胺类药物。为与美国国家临床实验室标准委员会单独针对头孢哌酮的解释性折点保持一致,以下MIC折点应适用于该组合(2:1比例):小于或等于16/8微克/毫升,敏感;32/16微克/毫升,中度敏感;大于或等于64/32微克/毫升,耐药。

相似文献

引用本文的文献

5
Antibiotic resistance and epidemiological characteristics of polymyxin-resistant .耐多药鲍曼不动杆菌的抗生素耐药性及流行病学特征。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2024 May 28;49(5):737-747. doi: 10.11817/j.issn.1672-7347.2024.230567.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验